Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer

Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment...

Full description

Saved in:
Bibliographic Details
Published in:Molecular diagnosis & therapy 2014-10, Vol.18 (5), p.541
Main Authors: Inoue, Yuka, Hazama, Shoichi, Iwamoto, Shigeyoshi, Miyake, Yasuhiro, Matsuda, Chu, Tsunedomi, Ryouichi, Okayama, Naoko, Hinoda, Yuji, Yamasaki, Takahiro, Suehiro, Yutaka, Yoshino, Shigefumi, Sakamoto, Junichi, Mishima, Hideyuki, Oka, Masaaki
Format: Article
Language:English
Subjects:
Cancer therapies
Colorectal cancer
Cytotoxicity
Drug therapy
Genes
Ligands
Metastasis
Mortality
Polymorphism
Response rates
Studies
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment C γ receptor) and EGFR (epidermal growth factor receptor) polymorphisms with the outcome of mCRC patients treated with cetuximab and FOLFIRI (folic acid/5-fluorouracil/irinotecan) as second-line therapy in the FLIER (Cetuximab Plus Folinic Acid/5-Fluorouracil/Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer as a Second-Line Treatment) study. A total of 57 patients were evaluated in this study. The association of each polymorphism with the response rate, progression-free survival, and overall survival was analyzed. The data suggest that FccR and EGFR CA repeat polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI, although further investigations will be needed to confirm the association of FccR and EGFR polymorphisms with the efficacy of cetuximab.
ISSN:1177-1062
1179-2000